Sight Sciences announced reimbursed procedural dry eye treatments at Novitas and First Coast with fee schedules for TearCare. The company reported gross margins as strong and highlighted growth in anterior segment and glaucoma markets including OMNI and cataract combo procedures. Market access expansion continues in dry eye and standalone glaucoma segments.
Tap to vote and see what everyone thinks.
OpenAI files for IPO as Altman's eye-scan firm lays off staff
Summary by ByteBrief